A landmark phase III clinical trial evaluating a chemotherapy-free regimen of aumolertinib combined with definitive radiotherapy for unresectable stage III non-small cell lung cancer harboring epidermal growth factor receptor mutations was terminated early. The decision followed the observation of a massive progression-free survival benefit. Researchers reported that the experimental treatment arm achieved a median progression-free survival of 34.0 months. By comparison, the control arm receiving standard concurrent chemoradiotherapy with cisplatin and pemetrexed reached just 7.4 months.
Aumolertinib Regimen Shatters Benchmarks
Inside the ADVANCE Trial Design
The prospective ADVANCE study tested the strategy of pairing 110 mg daily doses of the third-generation EGFR tyrosine kinase inhibitor aumolertinib with definitive radiotherapy, omitting traditional chemotherapy entirely. Trial documentation reveals that investigators planned to enroll 98 participants, assigned in a 1:1 ratio to either the experimental TKI-radiotherapy arm or the control chemoradiotherapy arm. Investigators halted the trial early during a prespecified interim analysis. They cited slow patient accrual, an open-label loss of equipoise, and a substantial difference in progression-free survival between the cohorts.
Survival Data and Real-World Validation
At a median follow-up of 25.5 months among the 43 randomized patients—24 in the experimental group and 19 in the control group—the hazard ratio for progression-free survival reached 0.15, favoring the aumolertinib-radiotherapy combination.
To validate these findings, researchers examined a protocol-prespecified real-world cohort comprising 125 patients with a median follow-up of 32.7 months. The real-world data demonstrated that EGFR tyrosine kinase inhibitors combined with radiotherapy, as well as TKIs combined with concurrent chemoradiotherapy, yielded similar outcomes that both surpassed standard chemoradiotherapy alone.
Toxicity Profiles and Quality of Life
Regarding treatment-related toxicities, adverse events such as neutropenia and nausea occurred more frequently in the traditional chemotherapy control arm.
Furthermore, patient-reported quality of life metrics favored the chemotherapy-sparing experimental arm. These findings align with broader clinical research trends in EGFR-mutant lung cancers, where newer third-generation tyrosine kinase inhibitors are increasingly studied to minimize chemotherapy toxicity while maintaining or improving oncological control.
Addressing Unresectable Stage III NSCLC
Lung cancer remains a leading cause of cancer-related deaths globally, with roughly 25 to 30 percent of newly diagnosed non-small cell lung cancer patients presenting with unresectable stage III disease. While standard treatment typically involves definitive concurrent chemoradiotherapy followed by consolidation immunotherapy, approximately 10 to 20 percent of stage III cases harbor EGFR mutations. Historical data, including subgroup analyses from the PACIFIC trial, indicate that standard consolidation immunotherapy does not improve survival in EGFR-mutated populations. This reality has prompted the investigation of alternative tailored approaches such as targeted TKI therapy combined directly with radiation.
Keep reading